Edition:
United States

Endo International PLC (ENDP.OQ)

ENDP.OQ on NASDAQ Stock Exchange Global Select Market

9.99USD
23 Mar 2017
Change (% chg)

-- (--)
Prev Close
$9.99
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
1,985,428
52-wk High
$35.34
52-wk Low
$9.70

Latest Key Developments (Source: Significant Developments)

Endo International former CEO Rajiv De Silva's FY 2016 compensation $19.2 mln vs $10.9 mln in FY 2015
Wednesday, 22 Mar 2017 04:14pm EDT 

Endo International Plc :Endo international plc - former ceo rajiv de silva's fy 2016 total compensation was $19.2 million versus $10.9 million in fy 2015 - sec filing.  Full Article

FDA staff: Difficult to assess impact of Opana ER’s reformulation on overall abuse of the drug
Thursday, 9 Mar 2017 09:33am EST 

Endo International Plc : FDA staff: postmarketing data suggests opana er reformulation likely reduced nasal abuse rates, but data limitations makes it hard to determine magnitude of effect . FDA staff: postmarketing data indicate an increase in opana er injection abuse rates over the study period .FDA staff: the data are difficult to interpret with regard to the impact of opana er’s reformulation on overall abuse of the drug (via any route)..  Full Article

Endo CEO says expects to launch about 20 products, generate about $100 million from those products in 2017
Tuesday, 28 Feb 2017 10:53am EST 

Endo International Plc : Endo CEO says newly-launched generic drugs Quetiapine & Ezetimibe generated close to $300 million in Q4 sales . Endo CEO: 2017 generic sales to decline in high single to low double-digit percentage range, partially offset by growth in sterile injectables & new launches . Endo CEO: sales of flagship branded product Xiaflex, driven primarily by double-digit demand growth, particularly in Peyronie's disease . Endo CEO: expects 2017 specialty business to grow in the high single digits, driven primarily by expected high single to low double-digit growth for Xiaflex . Endo CEO: portion of the cost savings from restructuring of co's pain business will be redeployed in 2017 to support core franchises, including Xiaflex . Endo CEO: says co has started due diligence process for the potential sale of somar business . Endo CFO: Q1 operating expenses expected to be largely in line with Q4 2016, due to the timing of certain expenses & recently announced restructuring initiatives . Endo CEO: "It will take some time to successfully address the challenges that endo faces today and it will take time to reposition endo for long-term success." . Endo CEO: "At this time we're not going to be able to guide beyond where we are in 2017" . Endo CEO says expects to launch about 20 products and generate about $100 million from those products in 2017.  Full Article

Endo Q4 adjusted earnings $1.77/shr from continuing operations
Tuesday, 28 Feb 2017 06:30am EST 

Endo International Plc : Endo International Plc - announces divestiture of Litha Healthcare Group for $100 million . Endo reports fourth-quarter and full-year 2016 financial results . Q4 adjusted earnings per share $1.77 from continuing operations . Q4 GAAP loss per share $14.96 from continuing operations . Sees FY 2017 revenue $3.45 billion to $3.6 billion . Q4 revenue $1.242 billion versus I/B/E/S view $1.16 billion . Q4 earnings per share view $1.63 -- Thomson Reuters I/B/E/S . Endo International Plc sees 2017 adjusted EBITDA from $1.50 billion to $1.58 billion . FY 2017 revenue view $3.83 billion -- Thomson Reuters I/B/E/S . Endo International Plc sees 2017 adjusted diluted EPS from continuing operations to be between $3.45 to $3.75 . FY 2017 earnings per share view $4.27 -- Thomson Reuters I/B/E/S . Endo International Plc sees 2017 reported diluted GAAP EPS from continuing operations to be between $0.04 and $0.34 .Endo International - reports $3.5 billion of asset impairment charges in fourth-quarter 2016 associated with write-down of goodwill and intangible assets.  Full Article

Endo's restructuring actions to reduce workforce by nearly 90 full-time positions
Thursday, 26 Jan 2017 06:30am EST 

Endo International Plc : Endo announces actions to drive greater efficiency and business alignment . Endo International - Restructuring actions primarily relate to co's corporate functions and Branded Pharmaceutical research and development functions in Malvern, PA and Chestnut Ridge, NY . Endo International Plc - Restructuring actions will reduce Endo's work force by approximately 90 full-time positions . Says Endo expects to realize approximately $40 million to $50 million in annual run rate pre-tax cost savings by q4 of 2017 . Endo International expects to realize about $40 million to $50 million in annual run rate pre-tax cost savings by Q4 of 2017 . Endo International Plc - Restructuring actions will result in restructuring cash charges of approximately $15 million to $20 million .Endo International expects to invest portion of cost savings in co's core product franchises and new product development programs.  Full Article

Endo says appointed Blaise Coleman as CFO
Tuesday, 20 Dec 2016 07:30am EST 

Endo International Plc : Endo International Plc - coleman has been serving as Endo's interim chief financial officer since November 22, 2016 .Endo announces appointment of Blaise Coleman as chief financial officer.  Full Article

BioDelivery Sciences reacquires license to BELBUCA from Endo Pharmaceuticals
Thursday, 8 Dec 2016 06:00am EST 

BioDelivery Sciences International Inc - : BioDelivery Sciences reacquires license to BELBUCA™ from Endo Pharmaceuticals . Endo will not be obligated to any future milestone payments to BDSI . Return of BELBUCA is expected to be accretive by improving BDSI's net income and earnings per share in 2017 . BDSI will also explore other options for longer-term growth for BELBUCA both within and ex-U.S . As a result of agreement, world-wide rights to BELBUCA will be transferred back to BDSI . Agreement goes into effect on January 6, 2017. . Specific financial terms of agreement have not been disclosed . Financial terms do not have a material impact on company's going forward cash runway . Total cost of transaction to BDSI will not materially impact BDSI's cash flow going forward .BDSI will not be responsible for future royalties or milestone payments to Endo.  Full Article

Endo International eliminating 375-member U.S. branded pain sales field force
Thursday, 8 Dec 2016 06:00am EST 

Endo International Plc - : It is eliminating its 375-member U.S. Branded pain sales field force . The strategic actions are expected to result in restructuring charges of approximately $62 million . Restructuring expected to provide approximately $90 million to $100 million in annual run rate pre-tax gross cost savings in 2017 . Anticipates a portion of cost savings to be redeployed in 2017 to support pursuit of development and approval of Xiaflex . Legacy pain portfolio products - including Opana ER and Percocet, among others will be managed as mature brands .Restructuring charges include a $40 million non-cash intangible asset impairment charge.  Full Article

Endo reports third quarter 2016 financial results
Tuesday, 8 Nov 2016 06:30am EST 

Endo International Plc : Endo International Plc - Company reaffirms full year 2016 revenues and adjusted diluted EPS financial guidance . FY2016 earnings per share view $4.55, revenue view $3.93 billion -- Thomson Reuters I/B/E/S . Endo reports third quarter 2016 financial results . Q3 adjusted earnings per share $1.01 from continuing operations . Q3 GAAP loss per share $0.86 from continuing operations . Q3 revenue $884 million versus I/B/E/S view $862.3 million .Q3 earnings per share view $0.81 -- Thomson Reuters I/B/E/S.  Full Article

Endo International names Paul Campanelli CEO
Friday, 23 Sep 2016 07:00am EDT 

Endo International PLC : Endo names Paul Campanelli president and chief executive officer . Company affirms Q3 and full year 2016 financial guidance . Campanelli succeeds Rajiv De Silva, who has stepped down as president, CEO and a member of board . Q3 earnings per share view $0.82, revenue view $864.5 million -- Thomson Reuters I/B/E/S .FY2016 earnings per share view $4.56, revenue view $3.93 billion -- Thomson Reuters I/B/E/S.  Full Article

More From Around the Web